105212-11-1

Basic information

• Product Name: 1-(4-BROMOBUTOXY)-2-BROMOBENZENE
• Synonyms: 4-(2-BROMOPHENOXY) BROMOBUTANE;1-(4-BROMOBUTOXY)-2-BROMOBENZENE;2-Bromophenoxybutylbromide;1-(4-Bromobutoxy)-2-bromobenzene,95%;1-BROMO-2-(4-BROMOBUTOXY)BENZENE
• CAS NO: 105212-11-1
• Molecular Formula: C₁₀H₁₂Br₂O
• Molecular Weight: 308.01
• Mol File: 105212-11-1.mol

Chemical Properties

• Boiling Point: 336.7°Cat760mmHg
• Flash Point: 136.8°C
• Appearance: /
• Density: 1.601g/cm³
• Vapor Pressure: 0.000215mmHg at 25°C
• Refractive Index: 1.5705-1.5725
• CAS DataBase Reference: 1-(4-BROMOBUTOXY)-2-BROMOBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMOBUTOXY)-2-BROMOBENZENE(105212-11-1)
• EPA Substance Registry System: 1-(4-BROMOBUTOXY)-2-BROMOBENZENE(105212-11-1)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-20/22
• Safety Statements: 37/39-26
• Hazardous Substances Data: 105212-11-1(Hazardous Substances Data)

Usage

Chemical Properties

clear slightly yellow liquid

InChI:InChI=1/C10H12Br2O/c11-7-3-4-8-13-10-6-2-1-5-9(10)12/h1-2,5-6H,3-4,7-8H2

Upstream product

• 33036-62-3 4-Bromo-1-butanol 
• 95-56-7 2-hydroxybromobenzene 
• 110-52-1 1,4-dibromo-butane 

Downstream Products

• 1004165-91-6 C₁₁H₁₆BrNO 

Relevant articles and documents

Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis

Effective strategies are needed to deal with invasive fungal infections caused by drug-resistant fungi. Previously, we designed a series of antifungal benzocyclane derivatives based on the drug repurposing of haloperidol. Herein, further structural optimization and antifungal mechanism studies were performed, leading to the discovery of new piperidol derivative B2 with improved synergistic antifungal potency, selectivity, and water solubility. In particular, the combination of compound B2 and fluconazole showed potent in vitro and in vivo antifungal activity against azole-resistant Candida albicans. Compound B2 inhibited important virulence factors by regulating virulence-associated genes and improved the efficacy of fluconazole by down-regulating the CYP51-coding gene and efflux pump gene. Taken together, the piperidol derivative B2 represents a promising lead compound for the combinational treatment of azole-resistant candidiasis.

Benzo aliphatic ring derivatives, and applications thereof

The invention discloses benzo aliphatic ring derivatives, and applications thereof. The benzo aliphatic ring derivatives are prepared through substation of benzo aliphatic ring compounds with nitrogenheterocyclic ring containing substituent groups. Most o

Discovery of highly potent novel antifungal azoles by structure-based rational design

On the basis of the active site of lanosterol 14α-demethylase from Candida albicans (CACYP51), a series of new azoles were designed and synthesized. All the new azoles show excellent in vitro activity against most of the tested pathogenic fungi, which represent a class of promising leads for the development of novel antifungal agents. The MIC80 value of compounds 8c, 8i and 8n against C. albicans is 0.001 μg/mL, indicating that these compounds are more potent than fluconazole, itraconazole and voriconazole. Flexible molecular docking was used to analyze the structure-activity relationships (SARs) of the compounds. The designed compounds interact with CACYP51 through hydrophobic, van der Waals and hydrogen-bonding interactions.

Synthesis of large ring macrocycles (12-18) by recyclable palladiumComplexed dendrimers on silica gel catalyzed intramolecular cyclocarbonylation reactions

Intramolecular cyclocarbonylation reactions with palladium-complexed dendrimers on silica gel as catalysts are very effective for the synthesis of twelveto eighteen-membered ring macrocycles. This process can tolerate a wide variety of functional groups,